🇺🇸 FDA
Pipeline program

Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

2019P000939

Phase 2 small_molecule completed

Quick answer

Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept for Thyroid Eye Disease is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Thyroid Eye Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials